✉  info@marketresearchfuture.com   ๐Ÿ“ž  +1 (855) 661-4441(US)   ๐Ÿ“ž  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major playersโ€™ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Ulcerative Colitis Market Research Report Information By Type (Ulcerative Proctitis, Proctosigmoiditis, Left-Sided Colitis, Pancolitis or Universal Colitis, and Fulminant Colitis), By Medication (5-Aminosalicylates, Steroids, Purine Analogs, Immunomodulators, and Biologics), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) โ€“ Market Forecast Till 2032.


ID: MRFR/Pharma/1737-HCR | 85 Pages | Author: Kinjoll Dey| April 2024

ย 


Ulcerative Colitis Market Segmentation


Ulcerative Colitis Type Outlook (USD Billion, 2019-2030)




  • Ulcerative Proctitis




  • Proctosigmoiditis




  • Left-Sided Colitis




  • Pancolitis or Universal Colitis




  • Fulminant Colitis




Ulcerative Colitis Medication Outlook (USD Billion, 2019-2030)




  • 5-Aminosalicylates




  • Steroids




  • Purine Analogs




  • Immunomodulators




  • Biologics




Ulcerative Colitis Regional Outlook (USD Billion, 2019-2030)




  • North America Outlook (USD Billion, 2019-2030)




    • North America Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • North America Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • US Outlook (USD Billion, 2019-2030)




    • US Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • US Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • CANADA Outlook (USD Billion, 2019-2030)




    • CANADA Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • CANADA Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics








  • Europe Outlook (USD Billion, 2019-2030)




    • Europe Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • Europe Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • Germany Outlook (USD Billion, 2019-2030)




    • Germany Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • Germany Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • France Outlook (USD Billion, 2019-2030)




    • France Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • France Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • UK Outlook (USD Billion, 2019-2030)




    • UK Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • UK Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • ITALY Outlook (USD Billion, 2019-2030)




    • ITALY Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • ITALY Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • SPAIN Outlook (USD Billion, 2019-2030)




    • Spain Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • Spain Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • Rest of Europe Outlook (USD Billion, 2019-2030)




    • Rest of Europe Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • REST OF EUROPE Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics








  • Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Asia-Pacific Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • Asia-Pacific Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • China Outlook (USD Billion, 2019-2030)




    • China Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • China Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • Japan Outlook (USD Billion, 2019-2030)




    • Japan Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • Japan Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • India Outlook (USD Billion, 2019-2030)




    • India Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • India Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • Australia Outlook (USD Billion, 2019-2030)




    • Australia Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • Australia Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • Rest of Asia-Pacific Outlook (USD Billion, 2019-2030)




    • Rest of Asia-Pacific Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • Rest of Asia-Pacific Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics








  • Rest of the World Outlook (USD Billion, 2019-2030)




    • Rest of the World Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • Rest of the World Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • Middle East Outlook (USD Billion, 2019-2030)




    • Middle East Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • Middle East Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • Africa Outlook (USD Billion, 2019-2030)




    • Africa Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • Africa Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics






    • Latin America Outlook (USD Billion, 2019-2030)




    • Latin America Ulcerative Colitis by Type




      • Ulcerative Proctitis




      • Proctosigmoiditis




      • Left-Sided Colitis




      • Pancolitis or Universal Colitis




      • Fulminant Colitis






    • Latin America Ulcerative Colitis by Medication




      • 5-Aminosalicylates




      • Steroids




      • Purine Analogs




      • Immunomodulators




      • Biologics










Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Please fill in Business Email for Quick Response

Table of Contents

1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5 GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE

5.1 ULCERATIVE PROCTITIS

5.2 PROCTOSIGMOIDITIS

5.3 LEFT-SIDED COLITIS

5.4 PANCOLITIS OR UNIVERSAL COLITIS

5.5 FULMINANT COLITIS

6. GLOBAL ULCERATIVE COLITIS MARKET, BY MEDICATION

6.1 5-AMINOSALICYLATES

6.2 STEROIDS

6.3 PURINE ANALOG

6.4 IMMUNOMODULATORS

6.5 BIOLOGICS

7. GLOBAL ULCERATIVE COLITIS MARKET, BY REGION

7.1 NORTH AMERICA

7.1.1 INTRODUCTION

7.2 EUROPE

72.1 INTRODUCTION

7.3 ASIA-PACIFIC

7.3.1 INTRODUCTION

7.4 MIDDLE EAST & AFRICA

7.4.1 INTRODUCTION

8. COMPETITIVE LANDSCAPE

8.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

8..1.1 STRATEGIC PARTNERSHIP

8..1.2 MERGER & ACQUISITION

9 COMPANY PROFILE

9.1 ABBVIE INC.

9.1.1 OVERVIEW

9.1.2 PRODUCT OVERVIEW

9.1.3 FINANCIALS

9.1.4 KEY DEVELOPMENTS

9.2 BAYER AG.

9.2.1 OVERVIEW

9.2.2 PRODUCT OVERVIEW

9.2.3 FINANCIALS

9.2.4 KEY DEVELOPMENTS

9.3 JOHNSON & JOHNSON SERVICES, INC.,

9.3.1 OVERVIEW

9.3.2 PRODUCT OVERVIEW

9.3.3 FINANCIALS

9.3.4 STRATEGY

9.3.5 KEY DEVELOPMENT

9.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED

9.4.1 OVERVIEW

9.4.2 PRODUCT OVERVIEW

9.4.3 FINANCIALS

9.4.4 KEY DEVELOPMENTS

9.5 PFIZER INC.

9.5.1 OVERVIEW

9.5.2 PRODUCT OVERVIEW

9.5.3 FINANCIALS

9.5.4 KEY DEVELOPMENTS

9.6 OTHERS

List of Tables

TABLE 1 GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE, 2013-2022 (USD MILLION)

TABLE 2 GLOBAL ULCERATIVE COLITIS MARKET, BY MEDICATION, 2013-2022 (USD MILLION)

TABLE 3 GLOBAL ULCERATIVE COLITIS MARKET BY REGION 2013-2022 (USD MILLION)

List of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL ULCERATIVE COLITIS MARKET, BY TYPE

FIGURE 4 GLOBAL ULCERATIVE COLITIS MARKET, BY MEDICATION

FIGURE 5 GLOBAL ULCERATIVE COLITIS MARKET, BY REGION

FIGURE 6 GLOBAL ULCERATIVE COLITIS MARKET: COMPANY SHARE ANALYSIS, 2015 (%)

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.
Related Reports
report-img
Gastrointestinal Drugs Market Research Report- Forecast till 2032
report-img
Global Lower GI Series Market Research Report- Forecast till 2030
report-img
Inflammatory Bowel Disease Treatment Market Research Report โ€“ Forecast to 2030
Press Release
pr-img
Ulcerative Colitis Market is Expected to Grow at a CAGR of 5.20% from 2022 to 2030
Logo
Dmca Cloudflare ssl
Paypal footer Ssl
Services Industry Expertise Consulting Services Articles How To Order FAQs
Our Company About US Careers Contact Us Terms & Conditions Privacy Policy
Banking Partners
Amex Mastercard1
Razerpay
Hdfcbank
Visa
✉  info@marketresearchfuture.com
๐Ÿ“ž  +1 (855) 661-4441(US)
๐Ÿ“ž  +44 1720 412 167(UK)

ยฉ 2024 Market Research Future ยฎ (Part of WantStats Reasearch And Media Pvt. Ltd.)